ViroVet

ViroVet, a Belgium-based biotechnology and pharmaceutical startup, is dedicated to combating the widespread threat of rapidly-transmitted viral illnesses within the livestock industry. The company's slogan "ViroVet aims to reduce livestock diseases with innovative virus control solutions and partnerships" encapsulates its mission. Since its establishment in 2015, ViroVet has focused on developing pioneering virus control solutions through collaboration with an extensive network of academic and industrial partners. The company's recent achievement includes securing a significant €6.00M Series B investment on 28 May 2020, with participation from notable investors such as Capricorn Venture Partners, Seventure Partners, PMV, KU Leuven Research & Development, Agri Investment Fund, Fonds Vives II (University of Louvain, UCL), Biotech Fund Flanders, and KU Leuven. This injection of capital is a testament to the market's confidence in ViroVet's innovative approach and the potential impact of its solutions. With its strong financial backing and a robust network of collaborators, ViroVet is well-positioned to continue its vital work in enhancing the health and economic value of livestock. As the company continues to advance in its field, it stands as an intriguing prospect for investors seeking opportunities in the biotechnology and pharmaceutical industries.